Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Loa Loa (eye worm) | TAR-binding protein | 0.0061 | 1 | 1 |
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Brugia malayi | TAR-binding protein | 0.0061 | 1 | 1 |
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Onchocerca volvulus | Neuropeptide F receptor homolog | 0.0008 | 0 | 0.5 |
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 1 | 1 |
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 1 | 1 |
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Echinococcus multilocularis | tar DNA binding protein | 0.0061 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0061 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 1 | 1 |
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0061 | 1 | 1 |
Onchocerca volvulus | Dopamine\/Ecdysteroid receptor homolog | 0.0008 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 1 | 1 |
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Brugia malayi | RNA recognition motif domain containing protein | 0.0061 | 1 | 1 |
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Onchocerca volvulus | 0.0008 | 0 | 0.5 | |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 1 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0061 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.